88625-23-4Relevant articles and documents
5-Alkylamino-N-phenylpyrazine-2-carboxamides: Design, preparation, and antimycobacterial evaluation
Ambro?kiewicz, Weronika,Bárta, Pavel,Dole?al, Martin,Jand'ourek, Ond?ej,Kone?ná, Klára,Ku?erová-Chlupá?ová, Marta,Paterová, Pavla,Vin?ová, Jarmila,Zitko, Jan
, (2020)
According to the World Health Organization, tuberculosis is still in the top ten causes of death from a single infectious agent, killing more than 1.7 million people worldwide each year. The rising resistance developed by Mycobacterium tuberculosis against currently used antituberculars is an imperative to develop new compounds with potential antimycobacterial activity. As a part of our continuous research on structural derivatives of the first-line antitubercular pyrazinamide, we have designed, prepared, and assessed the in vitro whole cell growth inhibition activity of forty-two novel 5-alkylamino-N-phenylpyrazine-2-carboxamides with various length of the alkylamino chain (propylamino to octylamino) and various simple substituents on the benzene ring. Final compounds were tested against Mycobacterium tuberculosis H37Ra and four other mycobacterial strains (M. aurum, M. smegmatis, M. kansasii, M. avium) in a modified Microplate Alamar Blue Assay. We identified several candidate molecules with micromolar MIC against M. tuberculosis H37Ra and low in vitro cytotoxicity in HepG2 cell line, for example, N-(4-hydroxyphenyl)-5-(pentylamino)pyrazine-2-carboxamide (3c, MIC = 3.91 μg/mL or 13.02 μM, SI > 38) and 5-(heptylamino)-N-(p-tolyl)pyrazine-2-carboxamide (4e, MIC = 0.78 μg/mL or 2.39 μM, SI > 20). In a complementary screening, we evaluated the in vitro activity against bacterial and fungal strains of clinical importance. We observed no antibacterial activity and sporadic antifungal activity against the Candida genus.
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132)
Barrish, Joel C.,Behnia, Kamelia,Bolton, Scott,Brigance, Robert P.,Cap, Michael,Chen, Bang-Chi,Chen, Sean,Chen, Xue-Qing,Cheng, Peter T. W.,Ellsworth, Bruce,Everlof, Gerry,Fuentes-Catanio, Helen G.,Fura, Aberra,Griffen, Steven,Gupta, Anuradha,Janovitz, Evan B.,Jones, Beverly,Kalinowski, Stephen,Kirby, Mark,Kopcho, Lisa,Krupinski, John,Krystek, Stanley R.,Kunselman, Lori,Langish, Robert A.,Leith, Leslie W.,Li, Yi-Xin,Liu, Heng,Ma, Xiaohui,Marcinkeviciene, Jovita,Mathur, Arvind,Meng, Wei,Muckelbauer, Jodi K.,Nielsen, Laura,O'Malley, Kevin,Pannacciulli, Nicola,Rampulla, Richard,Robl, Jeffrey A.,Ryono, Denis E.,Shi, Yan,Smirk, Rebecca,Spronk, Steven A.,Staal, Ada,Sulsky, Richard,Sun, Dawn,Sun, Jung-Hui,Swartz, Joann,Tao, Shiwei,Taylor, Joseph R.,Tino, Joseph A.,Wang, Aiying,Wang, Qi,Wang, Ying,Whaley, Jean,Williams, Kristin N.,Wong, Michael K. Y.,Wu, Dauh-Rurng,Xu, Carrie,Yang, Yanou,Zahler, Robert,Zalaznick, Jacob,Zebo, Rachel,Zhang, Hao,Zinker, Bradley A.
, p. 4291 - 4317 (2022/03/02)
Glucokinase (GK) is a key regulator of glucose homeostasis, and its small-molecule activators represent a promising opportunity for the treatment of type 2 diabetes. Several GK activators have been advanced into clinical trials and have demonstrated promising efficacy; however, hypoglycemia represents a key risk for this mechanism. In an effort to mitigate this hypoglycemia risk while maintaining the efficacy of the GK mechanism, we have investigated a series of amino heteroaryl phosphonate benzamides as ‘‘partial” GK activators. The structure-activity relationship studies starting from a “full GK activator” 11, which culminated in the discovery of the “partial GK activator” 31 (BMS-820132), are discussed. The synthesis and in vitro and in vivo preclinical pharmacology profiles of 31 and its pharmacokinetics (PK) are described. Based on its promising in vivo efficacy and preclinical ADME and safety profiles, 31 was advanced into human clinical trials.
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
Balazs, Amber,Barratt, Derek,Bista, Michal,Chuba, Matthew D.,Cosulich, Sabina,Critchlow, Susan E.,Degorce, Sébastien L.,Di Fruscia, Paolo,Edmondson, Scott D.,Embrey, Kevin,Fawell, Stephen,Ghosh, Avipsa,Gill, Sonja J.,Gunnarsson, Anders,Hande, Sudhir M.,Heightman, Tom D.,Hemsley, Paul,Illuzzi, Giuditta,Johannes, Jeffrey W.,Lane, Jordan,Larner, Carrie,Leo, Elisabetta,Liu, Lina,Madin, Andrew,Martin, Scott,McWilliams, Lisa,O'Connor, Mark J.,Orme, Jonathan P.,Pachl, Fiona,Packer, Martin J.,Pei, Xiaohui,Pike, Andrew,Schimpl, Marianne,She, Hongyao,Staniszewska, Anna D.,Talbot, Verity,Underwood, Elizabeth,Varnes, Jeffrey G.,Xue, Lin,Yao, Tieguang,Zhang, Andrew X.,Zhang, Ke,Zheng, Xiaolan
supporting information, p. 14498 - 14512 (2021/10/20)
Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA mutation. However, some have failed in combination with first-line chemotherapies, usually due to overlapping hematological toxicities. Currently approved PARP inhibitors lack selectivity for PARP1 over PARP2 and some other 16 PARP family members, and we hypothesized that this could contribute to toxicity. Recent literature has demonstrated that PARP1 inhibition and PARP1-DNA trapping are key for driving efficacy in a BRCA mutant background. Herein, we describe the structure- and property-based design of 25 (AZD5305), a potent and selective PARP1 inhibitor and PARP1-DNA trapper with excellent in vivo efficacy in a BRCA mutant HBCx-17 PDX model. Compound 25 is highly selective for PARP1 over other PARP family members, with good secondary pharmacology and physicochemical properties and excellent pharmacokinetics in preclinical species, with reduced effects on human bone marrow progenitor cells in vitro.
Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro- N-(2′-methyl-3′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide. Structure-Activity Relationship and Preclinical Characterization
Ahirrao, Prajakta,Bakhle, Dhananjay,Bhankhede, Trupti,Bhonde, Mandar,Bokan, Sanjay,Budhe, Sagar,Dadke, Disha,Daler, Jagadeesh,Deshmukh, Gokul,George, Shaji K.,Gholve, Milind,Gundu, Jaysagar,Gupta, Rajesh,Ingawale, Sachin,Irlapatti, Nageswara Rao,Jachak, Santosh,Kalia, Anil,Kamalakannan, Prabakaran,Kamboj, Rajender Kumar,Kanoje, Vijay,Karche, Vijay,Khedkar, Nilesh Raghunath,Kizhakinagath, Praveenkumar Anidil,Kuldharan, Sandip,Kumar, Hemant,Kumar, Swaroop,Mallurwar, Sadanand,Mehta, Maneesh,Modi, Dipak,Naik, Kumar,Narasimham, Lakshmi,Nemade, Harshal Narendra,Nemmani, Kumar V. S.,Nigade, Prashant,Padiya, Kamlesh J.,Palle, Venkata P.,Pandey, Dilip,Pareek, Himani,Patil, Amit,Patil, Vinod,Pawar, Shashikant,Phukan, Samiron,Shah, Chirag,Shaikh, Zubair,Shankar, Rajesh,Sharma, Nidhi,Sharma, Sharad,Shinde, Vikas,Sindkhedkar, Milind,Singh, Minakshi,Sinha, Neelima,Tamane, Kaustubh,Venugopal, Spinvin,Vishwase, Gururaj,Wagh, Akshaya,Yeshodharan, Rajesh
, p. 17004 - 17030 (2021/12/09)
The role of calcium release-activated calcium (CRAC) channels is well characterized and is of particular importance in T-cell function. CRAC channels are involved in the pathogenesis of several autoimmune diseases, making it an attractive therapeutic target for treating inflammatory diseases, like rheumatoid arthritis (RA). A systematic structure-activity relationship study with the goal of optimizing lipophilicity successfully yielded two lead compounds, 36 and 37. Both compounds showed decent potency and selectivity and a remarkable pharmacokinetic profile. Further characterization in in vivo RA models and subsequent histopathological evaluation of tissues led to the identification of 36 as a clinical candidate. Compound 36 displayed an excellent safety profile and had a sufficient safety margin to qualify it for use in human testing. Oral administration of 36 in Phase 1 clinical study in healthy volunteers established favorable safety, tolerability, and good target engagement as measured by levels of IL-2 and TNF-α.
